中药雾化治疗肿瘤化疗并发口腔溃疡62例临床观察

目的:观察中药雾化治疗肿瘤患者在化疗过程中并发口腔溃疡的临床疗效.方法:收集我院住院行化疗出现口腔溃疡患者120例,按患者自身情况及要求随即分为治疗组与对照组.其中治疗组62例,行口腔中药雾化,进行对症口腔溃疡的治疗;对照组58例,以常规口腔清洁及外用药物治疗.观察两组患者口腔溃疡疼痛的缓解程度及溃疡面的愈合时间.结果...     

苦参素注射液联合NP方案治疗老年晚期NSCLC近期疗效观察

目的观察苦参素注射液联合NP方案治疗老年晚期非小细胞肺癌（NSCLC）的效果。方法 60例老年晚期NSCLC患者随机分为观察组和对照组,各30例,分别采用苦参素注射液联合NP方案和单纯NP方案治疗。比较两组近期疗效及不良反应。结果观察组治疗有效率为83.4%,明显高于对照组的63.3%（P〈0.01）。观察组Ⅲ～Ⅳ级药物毒性反应发生率明显低于对照组（P〈0.05）。结论与单纯用NP方案比较,采用苦参素注射液联合NP方案治疗老年晚期NSCLC近期疗效较好,药物毒性反应低。     

经皮椎体成形术在多发椎体转移瘤中的应用

目的:探讨经皮胸腰椎体成形手术在多发性胸腰椎体转移瘤病人中应用的临床效果.方法:收集我院43例行经皮胸腰椎体成形术病人,其中胸腰椎体有压缩骨折(20例)与无椎体骨折(23例).观察术后患者局部疼痛缓解程度.并进行2-13个月随访,平均随访时间5.5个月.结果:胸腰椎体有压缩骨折组患者疼痛缓解明显,相反胸腰椎体无骨折患者疼痛缓解差.结论:经皮椎体成形术在多发胸腰椎体转移瘤患者应用中,要充分考虑椎体有无骨折预测术后止痛效果,以便让患者配合进一步治疗.     

紫杉醇脂质体联合5-Fu／CF新辅助化疗对胃癌细胞凋亡和增殖的影响

[目的]探讨紫杉醇脂质体联合5-氟尿嘧啶（5-Fu）／亚叶酸钙（CF）新辅助化疗方案对胃癌细胞凋亡率和增殖率的影响及机制。[方法]应用TUNEL检测凋亡率，SP免疫组化方法检测增殖率和survivin、bcl-2及bax表达情况。[结果]给予新辅助化疗后胃癌细胞凋亡率28．87％±3．05％，增殖率37．26％±2．06％，survivin表达阳性率43．08％，bax表达阳性率47．69％，与化疗前相对指标比较（13．76％±2．37％、56．17％±1．26％、72131％和23．08％），差异有统计学意义（P〈0．05）。[结论]以紫杉醇脂质体＋5-Fu／CF作为胃癌术前辅助化疗方案，可以明显提高胃癌细胞凋亡率和抑制其增殖率，其机制可能与下调survivin表达和bcl-2／bax比例有关。     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

目的 观察并比较多西他赛联合卡培他滨与奥沙利铂联合卡培他滨治疗老年晚期胃癌的近期疗效和不良反应.方法 82例老年晚期胃癌患者随机分为2组:多西他赛组38例,应用多西他赛(75mg/m2,静脉滴注1 h,第1天)联合卡培他滨[2000 mg/(m2·d),分2次口服,第1～14天]治疗,停服1周,第21天重复治疗;奥沙利铂组44例应用奥沙利铂(100 mg/m2,静脉滴注1 h,第1天)联合卡培他滨(剂量同上)治疗;21 d为1个周期,均化疗2个周期以上,2个周期后复查评价疗效.结果 82例均完成随访,多西他赛组有效率为52.63%(20/38),中位无进展生存期(PFS)为6.1个月.奥沙利铂组有效率为54.55%(24/44),PFS为6.3个月.2组有效率(χ2=0.030,P=0.862)和PFS(χ2=1.39,P=0.19)差异均无统计学意义.2组患者主要不良反应为胃肠反应和骨髓抑制;神经毒性也较常见,多为Ⅰ度或Ⅱ度毒性反应,Ⅲ度或Ⅳ度毒性反应少见,主要为恶心呕吐、白细胞和血小板计数降低.2组间各项不良反应发生率差异无统计学意义(P均>0.05),均无化疗相关性死亡.结论 多西他赛联合卡培他滨与奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效相当,不良反应均可耐受.     

经骶管用药对减轻肺癌胸背部疼痛的疗效性分析

目的 探讨曲安奈德稀释液经骶管注入硬膜外腔对减轻晚期肺癌椎体转移的临床效果.方法 收集我院2005年3月至2008年10月61例晚期肺癌患者,按患者自身情况及要求随即分为实验组与对照组.其中实验组34例行曲安奈德稀释液硬膜外用药;对照组27例行麻醉镇痛.观察患者因椎体转移出现胸背部疼痛的缓解程度.并进行1-3个月随访,平均随访时间达1.2个月.结果 实验组胸背部疼痛缓解时间明显缩短.结论 曲安奈德稀释液经骶管注入硬膜外腔对减轻晚期肺癌椎体转移出现胸背疼痛的临床效果佳.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

人宫颈癌移植瘤乏氧动物模型的建立及鉴定

 目的　建立人宫颈癌移植瘤乏氧动物模型并进行鉴定。方法　人宫颈癌Hela细胞接种于裸小鼠右后大腿外侧皮下 ,每鼠 0 .2ml。待肿瘤长至瘤体溃烂前 (1.7cm左右 ) ,用双通道组织氧分压传感针测定肿瘤及正常组织的氧分压 ,取肿瘤组织作常规病理检查 ,并用免疫组化方法检测肿瘤组织乏氧诱导因子 1α表达。结果　 (1) 8只裸鼠 ,7只成活 ,其中 7只成瘤 ,成瘤率 87.5 % (7/ 8)。瘤体平均大小1.75 85± 0 .2 0 2 0cm。 (2 )移植瘤乏氧状况测定 ,瘤体平均氧分压为 3.785 7± 0 .6 6 94kPa,明显处于乏氧状况 ,而作为对照的正常后腿氧分压为 11.7714± 2 .2 787kPa (t=7.6 78,P <0 .0 1)。 (3) 7只小鼠移植瘤的病理检查均为上皮性癌 ,HIF 1α表达均为强阳性 (+++)。结论　人宫颈癌移植瘤瘤体大小生长至瘤体溃烂前 (1.7cm左右 ) ,是一种较好与临床实际情况相符 ,适合研究需要 ,成功率较高的人宫颈癌移植瘤乏氧模型